Axsome Therapeutics (AXSM) Revenue (2022 - 2026)

Axsome Therapeutics' Revenue history runs 5 years deep, the most recent figure standing at $191.2 million for Q1 2026.

• In Q1 2026, Revenue rose 57.42% year-over-year to $191.2 million; the TTM figure through Mar 2026 stood at $708.2 million (up 125.63% YoY), while the FY2025 annual figure was $638.5 million, up 65.55% from the prior year.
• Revenue came in at $191.2 million for Q1 2026 at Axsome Therapeutics, down from $196.0 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $196.0 million in Q4 2025 to a low of $500000.0 in Q4 2024.
• A 5-year average of $88.6 million and a median of $81.1 million in 2024 frame the typical range for Revenue.
• Across the five-year window, Revenue sank 99.3% in 2024 and soared 39099.8% in 2025, its largest moves.
• Axsome Therapeutics' Revenue stood at $24.4 million in 2022, then jumped by 193.5% to $71.5 million in 2023, then tumbled by 99.3% to $500000.0 in 2024, then jumped by 39099.8% to $196.0 million in 2025, then dropped by 2.45% to $191.2 million in 2026.
• According to Business Quant data, Revenue over the past three periods registered $191.2 million, $196.0 million, and $171.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison